Avallon Pharma extends Riyal 50M credit with Al-Inma
Alvion Pharma, the Middle East Pharmaceuticals Company, has renewed a credit facilities agreement with Alinma Bank valued at 50 million Saudi Riyals for a period of one year, starting from August 19, 2026. The purpose of this financing is to support working capital and capital expenditures to ensure operational continuity and expansion, with a promissory note provided to guarantee the company's commitment. There are no related parties involved in the agreement, which enhances transparency. This move is part of the company's strategy to diversify funding sources and support growth in the pharmaceutical sector in line with Saudi Arabia’s Vision 2030.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)